메뉴 건너뛰기




Volumn 5, Issue 2, 2009, Pages 66-67

RADIATE: More treatment options for patients with an inadequate response to tumor necrosis factor antagonists

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 59849098178     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0984     Document Type: Note
Times cited : (10)

References (9)
  • 1
    • 33846239331 scopus 로고    scopus 로고
    • Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
    • Hyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 56: 13-20
    • (2007) Arthritis Rheum , vol.56 , pp. 13-20
    • Hyrich, K.L.1
  • 2
    • 40749114497 scopus 로고    scopus 로고
    • Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebocontrolled, randomised trial
    • Smolen JS et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebocontrolled, randomised trial. Lancet 371: 987-997
    • (2008) Lancet , vol.371 , pp. 987-997
    • Smolen, J.S.1
  • 3
    • 54949150604 scopus 로고    scopus 로고
    • Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
    • Genovese MC et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968-2980
    • (2008) Arthritis Rheum , vol.58 , pp. 2968-2980
    • Genovese, M.C.1
  • 4
    • 52149099504 scopus 로고    scopus 로고
    • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial
    • Emery P et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67: 1516-1523
    • (2008) Ann Rheum Dis , vol.67 , pp. 1516-1523
    • Emery, P.1
  • 5
    • 34447300492 scopus 로고    scopus 로고
    • Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab
    • Nishimoto N et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 1162-1167
    • (2007) Ann Rheum Dis , vol.66 , pp. 1162-1167
    • Nishimoto, N.1
  • 6
    • 34248545097 scopus 로고    scopus 로고
    • B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
    • Finckh A et al. (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56: 1417-1423
    • (2007) Arthritis Rheum , vol.56 , pp. 1417-1423
    • Finckh, A.1
  • 7
    • 54349105781 scopus 로고    scopus 로고
    • Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized, double-blind, placebo-control trial [abstract #OP-0010]
    • Smolen J et al. (2008) Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized, double-blind, placebo-control trial [abstract #OP-0010]. Ann Rheum Dis 67 (suppl 2): 50
    • (2008) Ann Rheum Dis , vol.67 , Issue.SUPPL. 2 , pp. 50
    • Smolen, J.1
  • 8
    • 33746961890 scopus 로고    scopus 로고
    • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    • Cohen SB et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793-2806
    • (2006) Arthritis Rheum , vol.54 , pp. 2793-2806
    • Cohen, S.B.1
  • 9
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    • Genovese MC et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114-1123
    • (2005) N Engl J Med , vol.353 , pp. 1114-1123
    • Genovese, M.C.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.